vs
安道拓（ADNT）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是安道拓的1.3倍（$4.7B vs $3.6B），梯瓦制药净利率更高（10.2% vs -0.6%，领先10.8%），梯瓦制药同比增速更快（11.4% vs 4.3%），梯瓦制药自由现金流更多（$1.0B vs $15.0M），过去两年梯瓦制药的营收复合增速更高（11.1% vs -1.4%）
安道拓是全球规模最大的汽车座椅制造商，注册地位于爱尔兰，运营总部设在美国密歇根州普利茅斯，业务覆盖全球各地，为全球客户提供专业的汽车座椅相关产品及解决方案，在汽车座椅领域拥有领先的市场地位与技术优势。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
ADNT vs TEVA — 直观对比
营收规模更大
TEVA
是对方的1.3倍
$3.6B
营收增速更快
TEVA
高出7.1%
4.3%
净利率更高
TEVA
高出10.8%
-0.6%
自由现金流更多
TEVA
多$1.0B
$15.0M
两年增速更快
TEVA
近两年复合增速
-1.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $4.7B |
| 净利润 | $-22.0M | $481.0M |
| 毛利率 | 6.0% | 56.4% |
| 营业利润率 | 1.1% | 6.4% |
| 净利率 | -0.6% | 10.2% |
| 营收同比 | 4.3% | 11.4% |
| 净利润同比 | — | 321.7% |
| 每股收益（稀释后） | $-0.28 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADNTTEVA
| Q4 25 | $3.6B | $4.7B | ||
| Q3 25 | $3.7B | $4.5B | ||
| Q2 25 | $3.7B | $4.2B | ||
| Q1 25 | $3.6B | $3.9B | ||
| Q4 24 | $3.5B | $4.2B | ||
| Q3 24 | $3.6B | $4.3B | ||
| Q2 24 | $3.7B | $4.2B | ||
| Q1 24 | $3.8B | $3.8B |
净利润ADNTTEVA
| Q4 25 | $-22.0M | $481.0M | ||
| Q3 25 | $18.0M | $433.0M | ||
| Q2 25 | $36.0M | $282.0M | ||
| Q1 25 | $-335.0M | $214.0M | ||
| Q4 24 | $0 | $-217.0M | ||
| Q3 24 | $79.0M | $-437.0M | ||
| Q2 24 | $-11.0M | $-846.0M | ||
| Q1 24 | $-70.0M | $-139.0M |
毛利率ADNTTEVA
| Q4 25 | 6.0% | 56.4% | ||
| Q3 25 | 6.7% | 51.4% | ||
| Q2 25 | 6.3% | 50.3% | ||
| Q1 25 | 7.2% | 48.2% | ||
| Q4 24 | 6.2% | 50.2% | ||
| Q3 24 | 6.9% | 49.6% | ||
| Q2 24 | 5.6% | 48.6% | ||
| Q1 24 | 6.1% | 46.4% |
营业利润率ADNTTEVA
| Q4 25 | 1.1% | 6.4% | ||
| Q3 25 | 1.7% | 19.7% | ||
| Q2 25 | 1.8% | 10.9% | ||
| Q1 25 | -7.3% | 13.3% | ||
| Q4 24 | 1.3% | -0.7% | ||
| Q3 24 | 1.8% | -1.2% | ||
| Q2 24 | 1.2% | -0.1% | ||
| Q1 24 | -1.1% | -5.7% |
净利率ADNTTEVA
| Q4 25 | -0.6% | 10.2% | ||
| Q3 25 | 0.5% | 9.7% | ||
| Q2 25 | 1.0% | 6.8% | ||
| Q1 25 | -9.3% | 5.5% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | 2.2% | -10.1% | ||
| Q2 24 | -0.3% | -20.3% | ||
| Q1 24 | -1.9% | -3.6% |
每股收益（稀释后）ADNTTEVA
| Q4 25 | $-0.28 | $0.42 | ||
| Q3 25 | $0.17 | $0.37 | ||
| Q2 25 | $0.43 | $0.24 | ||
| Q1 25 | $-3.99 | $0.18 | ||
| Q4 24 | $0.00 | $-0.19 | ||
| Q3 24 | $0.88 | $-0.39 | ||
| Q2 24 | $-0.12 | $-0.75 | ||
| Q1 24 | $-0.77 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.6B |
| 总债务越低越好 | $2.4B | — |
| 股东权益账面价值 | $1.7B | $7.9B |
| 总资产 | $8.8B | $40.7B |
| 负债/权益比越低杠杆越低 | 1.37× | — |
8季度趋势，按日历期对齐
现金及短期投资ADNTTEVA
| Q4 25 | — | $3.6B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.3B | ||
| Q1 24 | — | $3.0B |
总债务ADNTTEVA
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益ADNTTEVA
| Q4 25 | $1.7B | $7.9B | ||
| Q3 25 | $1.8B | $7.3B | ||
| Q2 25 | $1.8B | $6.8B | ||
| Q1 25 | $1.7B | $6.3B | ||
| Q4 24 | $1.9B | $5.4B | ||
| Q3 24 | $2.1B | $6.1B | ||
| Q2 24 | $1.9B | $6.4B | ||
| Q1 24 | $2.1B | $7.3B |
总资产ADNTTEVA
| Q4 25 | $8.8B | $40.7B | ||
| Q3 25 | $9.0B | $39.9B | ||
| Q2 25 | $8.8B | $40.1B | ||
| Q1 25 | $8.6B | $38.4B | ||
| Q4 24 | $8.5B | $39.3B | ||
| Q3 24 | $9.4B | $41.8B | ||
| Q2 24 | $9.1B | $41.3B | ||
| Q1 24 | $9.3B | $42.8B |
负债/权益比ADNTTEVA
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $80.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $15.0M | $1.0B |
| 自由现金流率自由现金流/营收 | 0.4% | 21.6% |
| 资本支出强度资本支出/营收 | 1.8% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 2.41× |
| 过去12个月自由现金流最近4个季度 | $174.0M | $1.1B |
8季度趋势，按日历期对齐
经营现金流ADNTTEVA
| Q4 25 | $80.0M | $1.2B | ||
| Q3 25 | $213.0M | $369.0M | ||
| Q2 25 | $172.0M | $227.0M | ||
| Q1 25 | $-45.0M | $-105.0M | ||
| Q4 24 | $109.0M | $575.0M | ||
| Q3 24 | $263.0M | $693.0M | ||
| Q2 24 | $158.0M | $103.0M | ||
| Q1 24 | $81.0M | $-124.0M |
自由现金流ADNTTEVA
| Q4 25 | $15.0M | $1.0B | ||
| Q3 25 | $134.0M | $233.0M | ||
| Q2 25 | $115.0M | $131.0M | ||
| Q1 25 | $-90.0M | $-232.0M | ||
| Q4 24 | $45.0M | $446.0M | ||
| Q3 24 | $191.0M | $545.0M | ||
| Q2 24 | $88.0M | $6.0M | ||
| Q1 24 | $12.0M | $-248.0M |
自由现金流率ADNTTEVA
| Q4 25 | 0.4% | 21.6% | ||
| Q3 25 | 3.6% | 5.2% | ||
| Q2 25 | 3.1% | 3.1% | ||
| Q1 25 | -2.5% | -6.0% | ||
| Q4 24 | 1.3% | 10.5% | ||
| Q3 24 | 5.4% | 12.6% | ||
| Q2 24 | 2.4% | 0.1% | ||
| Q1 24 | 0.3% | -6.5% |
资本支出强度ADNTTEVA
| Q4 25 | 1.8% | 3.0% | ||
| Q3 25 | 2.1% | 3.0% | ||
| Q2 25 | 1.5% | 2.3% | ||
| Q1 25 | 1.2% | 3.3% | ||
| Q4 24 | 1.8% | 3.1% | ||
| Q3 24 | 2.0% | 3.4% | ||
| Q2 24 | 1.9% | 2.3% | ||
| Q1 24 | 1.8% | 3.2% |
现金转化率ADNTTEVA
| Q4 25 | — | 2.41× | ||
| Q3 25 | 11.83× | 0.85× | ||
| Q2 25 | 4.78× | 0.80× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.33× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADNT
暂无分部数据
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
